Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE, OTCQX:ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration ("FDA") that otenaproxesul has been placed on
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of
Antibe Therapeutics Non-GAAP EPS of -C$0.08
Antibe Reports Q3 2024 Interim Financial and Operating Results
- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive design - Ended quarter
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early
Stocks in Play: Antibe Therapeutics Inc.
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF) (the "Company"), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces
Antibe Therapeutics Reports Q2 Results
Antibe Completes First Clinical Study of Otenaproxesul's New Formulation
- All treatments well tolerated with no adverse safety signals - No elevations in liver enzymes Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health
Antibe Announces Results of 2023 Annual Meeting
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.The View From Th
Antibe Therapeutics GAAP EPS of -C$0.11
Antibe Reports Q1 2024 Interim Financial and Operating Results
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and
Antibe Therapeutics Inc.'s (TSE:ATE) Path To Profitability
Antibe Therapeutics GAAP EPS of -$0.37
No Data